Journal of Clinical Medicine
Cutaneous Events After Recombinant Zoster Vaccination and Shoulder Injury Related to Zoster Vaccine Administration: A Narrative Review
By Carlo Ciccullo, Arturo Ciccullo, Sonia Farah and 8 others.
Abstract
Background
Herpes zoster results from the reactivation of varicella–zoster virus (VZV), with incidence increasing with age and immunosuppression. The recombinant zoster vaccine (RZV, Shingrix®, GlaxoSmithKline Biologicals SA, Rixensart, Belgium) has demonstrated high efficacy in preventing herpes zoster and its complications.
